

SARISSA CAPITAL
M A N A G E M E N T L P

Innoviva Investor Presentation
April 12, 2017

SPECIAL NOTE REGARDING THIS PRESENTATION

ON MARCH 22, 2017, SARISSA CAPITAL MANAGEMENT LP ("SARISSA"), TOGETHER WITH THE OTHER PARTICIPANTS IN SARISSA'S PROXY SOLICITATION (THE "PARTICIPANTS"), FILED A DEFINITIVE PROXY STATEMENT AND ACCOMPANYING GOLD PROXY CARD WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC") TO BE USED TO SOLICIT PROXIES IN CONNECTION WITH THE 2017 ANNUAL MEETING OF SHAREHOLDERS OF INNOVIVA, INC. (THE "COMPANY"). SHAREHOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES FROM THE SHAREHOLDERS OF THE COMPANY BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING INFORMATION RELATING TO THE PARTICIPANTS. THE DEFINITIVE PROXY STATEMENT AND A FORM OF PROXY IS AVAILABLE TO SHAREHOLDERS OF THE COMPANY AT NO CHARGE AT THE SEC'S WEBSITE AT WWW.SEC.GOV. THE DEFINITIVE PROXY STATEMENT AND A FORM OF PROXY IS ALSO AVAILABLE BY CONTACTING SARISSA'S PROXY SOLICITOR, D.F. KING & CO., INC., BY TELEPHONE AT THE FOLLOWING NUMBERS: STOCKHOLDERS CALL TOLL-FREE: (800) 549-6746 AND BANKS AND BROKERAGE FIRMS CALL: (212) 269-5550, OR THROUGH THE INTERNET AT WWW.DFKING.COM/INVA.

This presentation includes information based on data found in filings with the SEC, independent industry publications and other sources. Although the Participants believe that the data is reliable, they do not guarantee the accuracy or completeness of this information and have not independently verified any such information. Many of the statements in this presentation reflect the Participants' subjective belief. Although they have reviewed and analyzed the information that has informed their opinions, they do not guarantee the accuracy of any such beliefs. They have not sought, nor have they received, permission from any third-party to include their information in this presentation.

Summary

- Sarissa believes that Innoviva's directors Barbara Duncan, Catherine J. Friedman, Patrick G. LePore, Paul A. Pepe, James L. Tyree and William H. Waltrip have breached their fiduciary duties by (1) overpaying their executives and (2) overpaying themselves

INNOVIVA DOES NOT MARKET OR SELL ANY DRUGS. IT JUST COLLECTS ROYALTY PAYMENTS. SO WHY IS INNOVIVA'S SPENDING AND COMPENSATION SO EXORBITANT?

IT IS TIME FOR INNOVIVA TO BE OPTIMIZED FOR SHAREHOLDERS

Biospecifics Technologies Corp. currently collects royalties on 1 drug...

Total compensation of Principal Executive Officer in 2015 → **\$354K**

DEF 14A filed April 2016

Name And Principal Position	Year	Salary (\$)(2)	All Other Compensation (\$)	Total (\$)
Thomas Wegman President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer (1)	2015	350,000	3,607(4)	353,607
	2014	350,000(3)	3,325(4)	353,325
	2013	320,833(3)	2,828(4)	323,661

Biospecifics Technologies collects royalties on its injectable collagenase, marketed as XI AFLEX® by Endo International plc. Biospecifics Technologies is developing the collagenase in additional indications and in first quarter 2017 expected to initiate a clinical trial in uterine fibroids

Enzon Pharmaceuticals currently collects royalties on 4 drugs...

Total compensation of Principle Executive Officer in 2015 → **\$40K**

DEF 14A filed May 2016

Name and Principal Position	Year	Salary (\$) ⁽¹⁾	Stock Awards (\$)	Option Awards (\$)	Non-Equity Incentive Plan Compensation (\$)	All Other Compensation (\$) ⁽²⁾	Total (\$)
George W. Hebard III Former Interim Principal Executive Officer, Interim Chief Operating Officer and Secretary	2015	—	—	—	—	40,250	40,250
	2014	—	—	—	—	64,708	64,708
Richard L. Feinstein Vice President - Finance and Chief Financial Officer	2015	—	—	—	—	123,964	123,964
	2014	—	—	—	—	138,094	138,094

Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron[®], Sylatron[®], Macugen[®] and CIMZIA[®]

Innoviva currently collects royalties on 2 drugs...

Total compensation of CEO in 2015 → **\$3.6 million**

DEF 14A filed March 2016

Name and Principal Position	Year	Salary (\$)(1)	Bonus (\$)(d)	Stock Awards (\$)(2)	Option Awards (\$)(2)	Non-Equity Incentive Plan Compensation (\$)(3)	All Other Compensation (\$)(4)	Total (\$)(i)
(a)	(b)	(c)	(d)	(e)	(f)	(g)	(i)	(i)
Michael W. Aguiar	2016	746,688	—	2,159,152	—	672,019	19,667	3,597,526
President and Chief Executive Officer	2015	721,438	—	2,314,256	—	516,206	9,000	3,560,900
	2014	557,247	—	3,564,881	—	437,500	500	4,560,128

~10x the amount paid at Biospecifics;
~90x the amount paid at Enzon

Innoviva's current business is focused on collecting royalties from two respiratory inhalers sold and marketed by GSK

We believe the directors of Innoviva are failing to uphold their fiduciary duties by paying the CEO excessive multiples of what CEOs at other companies that simply collect royalties are paid

Non-executive directors at Innoviva

Barbara Duncan

Catherine J. Friedman

Member of Compensation Committee

Patrick G. LePore

Member of Compensation Committee

Paul A. Pepe

James L. Tyree

Chair of Compensation Committee

William H. Waltrip

Chairman

Biospecifics Technologies Corp. currently collects royalties on 1 drug...
 Median compensation of directors in 2015 → **\$68K**

DEF 14A filed April 2016

Name	Fees Earned or Paid in Cash (\$)(1)	Option Awards (\$)(2)(3)	Total (\$)
Dr. Paul Gitman(2)	65,000		65,000
Michael Schamroth(2)	65,000		65,000
Dr. Mark Wegman(2)	68,529 (4)		68,529 (4)
Toby Wegman(2)	22,000		22,000
George Gould (2)	68,377 (5)		68,377 (5)
Dr. Jyrki Mattila (3)	44,966	42,182	87,148
Ms. Jennifer Chao (3)	44,966	42,182	87,148

Biospecifics Technologies collects royalties on its injectable collagenase, marketed as XIAFLEX® by Endo International plc. Biospecifics Technologies is developing the collagenase in additional indications and in first quarter 2017 expected to initiate a clinical trial in uterine fibroids

Enzon Pharmaceuticals currently collects royalties on 4 drugs...
Median compensation of directors in 2015 → **\$35K**

DEF 14A filed May 2016

Name	Fees Earned or Paid in Cash (\$)	Stock Awards (\$) ⁽¹⁾	Option Awards (\$) ⁽²⁾	Total (\$)
Jonathan Christodoro	40,000	—	—	40,000
Odysseas Kostas	35,000	—	—	35,000
Jennifer I. McNealey	35,000	—	—	35,000

Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron[®], Sylatron[®], Macugen[®] and CIMZIA[®]

Innoviva currently collects royalties on 2 drugs...

Median compensation of directors in 2015 → \$330K

DEF 14A filed March 2016

Name (a)	Fees Earned or Paid in Cash (\$)(1) (b)	Stock Awards \$(2)(3) (c)	Total (\$) (d)
Catherine J. Friedman	70,000	249,984	319,984
Terrence C. Kearney	67,500	249,984	317,484
Paul A. Pepe	80,000	249,984	329,984
James L. Tyree	80,000	249,984	329,984
William H. Waltrip	112,500	249,984	362,484

~5x the amount paid
at Biospecifics;
~9x the amount paid
at Enzon

Innoviva's current business is focused on collecting royalties from two respiratory inhalers sold and marketed by GSK

Even more remarkable... in 2015 the median compensation of directors at Innoviva was >\$100K higher than Theravance Biopharma, the company that it spun off in 2014 that has a real operating business!

Innoviva


Non-executive director	Total compensation (2015)
Catherine J. Friedman	319,984
Terrence C. Kearney	317,484
Paul A. Pepe	329,984
James L. Tyree	329,984
William H. Waltrip	362,484
MEDIAN	329,984

Innoviva, unlike Theravance Biopharma, simply collects royalties

Theravance Biopharma, Inc.

Non-executive director	Total compensation (2015)
Eran Broshy	163,641
Henrietta H. Fore	193,293
Robert V. Gunderson, Jr.	196,577
Burton G. Malkiel, Ph.D.	233,125
Dean J. Mitchell	213,577
Susan Molineaux, Ph.D.	352,143
Donal O'Connor	162,189
Peter S. Ringrose	220,757
George M. Whitesides, Ph.D.	205,165
William D. Young	241,580
MEDIAN	209,371

Theravance Biopharma has a real operating business – marketed product, salesforce and extensive R&D pipeline – and yet lower director compensation than Innoviva!



We believe the directors at Innoviva are failing to uphold their fiduciary duties by paying themselves multiples of what directors at other companies that simply collect royalties are paid

Non-executive directors at Innoviva

Barbara Duncan

Catherine J. Friedman

Member of Compensation Committee

Patrick G. LePore

Member of Compensation Committee

Paul A. Pepe

James L. Tyree

Chair of Compensation Committee

William H. Waltrip

Chairman

Note, comparing compensation at Innoviva to other companies of similar size by revenue or market cap is misguided

- Unlike other companies in its peer group by size:
 - Innoviva does not sell or market drugs!
 - Innoviva does not engage in any real R&D!

We believe these are critical points to understanding Innoviva's compensation. In this context, compensation at Innoviva can be appreciated as especially egregious, a true extreme!

In light of Innoviva's excessive spending, including egregious compensation of management and directors

- Sarissa is gravely concerned that Innoviva will squander future royalty revenues on M&A (management has already expressed a desire to “build over time a recurring revenue business”)¹, additional overcompensation of management and directors and other misguided spending

¹CEO comments at Cowen Health Care Conference (March 2017)

Sarissa is particularly concerned that Innoviva will waste shareholder money on imprudent acquisitions

- Sarissa believes shareholders should not be confident that the current board and management team will make the right capital allocation decisions
- Sarissa is fearful that any imprudent acquisitions will irreversibly alter the strategic position of the company and thereby irreparably damage shareholder value
- Innoviva should clarify to shareholders its intentions regarding acquisitions

INNOVIVA DOES NOT MARKET OR SELL ANY DRUGS. IT JUST COLLECTS ROYALTY PAYMENTS. SO WHY IS INNOVIVA'S SPENDING AND COMPENSATION SO EXORBITANT?

IT IS TIME FOR INNOVIVA TO BE OPTIMIZED FOR SHAREHOLDERS

ISS, Glass Lewis and Egan-Jones all recommend that Innoviva shareholders vote on Sarissa's GOLD PROXY CARD

- ISS and Egan-Jones recommend all three Sarissa nominees and Glass Lewis recommends two Sarissa nominees
- All three recommend shareholders vote AGAINST Innoviva's executive compensation
- All three recommend shareholders NOT VOTE ON MANAGEMENT'S WHITE CARD

We urge you to VOTE THE GOLD PROXY CARD

- Time is of the essence. We urge you to VOTE THE GOLD PROXY CARD to help us fix the problems at Innoviva. If you want to follow the recommendations of ISS, Glass Lewis and Egan-Jones and vote for Sarissa nominees YOU MUST VOTE ON THE GOLD CARD AND YOU CANNOT VOTE THE WHITE CARD. Returning a white card, even if you withhold on Innoviva's nominees, will not be a vote for the Sarissa nominees, and it would revoke any vote you previously submitted on the GOLD CARD. PLEASE VOTE NOW by signing, dating and returning the GOLD proxy card or by voting by phone or internet.
- If you have any questions regarding your GOLD proxy card or need assistance in voting, please contact our proxy solicitor:

D.F. KING & CO., INC.

STOCKHOLDERS CALL TOLL-FREE: (800) 549-6746

BANKS AND BROKERAGE FIRMS CALL: (212) 269-5550

WWW.DFKING.COM/INVA



To be continued...

